 Arcturus Therapeutics Holdings Inc NASDAQ: ARCT announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying mRNA vaccine candidates for COVID-19. ARCT-154 and ARCT-165 are being studied in a Phase 12 trial in U.S. and Singapore. 